Business
Medicure Announces SMILE(TM)-HF Study Demonstrates Use of ReDS(TM) Results in 58% Reduction in Hospital Readmission Rate
Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% ...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\n\nMedicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, Oct. 15, 2019\n\n\n\nWINNIPEG, Oct. 15, 2019 /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the primary results of the late-breaking SMILETM-Heart Failure (SMILE-HF) Clinical Trial which was presented at the recent Heart Failure Society of America (\"HFSA\") conference in Philadelphia, PA by Dr. William T. Abraham, the SMILE-HF national principal investigator. \nThe SMILE-HF trial demonstrated that when used as intended, Remote Dielectric Sensing (ReDS™) treatment guided heart failure management prevented 58% of heart failure readmission(s). Data was collected from 268 patients by 43 centers across the United States, constituting the largest randomized control trial to date on the impact of ReDS™ on managing heart failure. Patients were recruited for the study during hospitalization and followed for up to 9 months at home. Daily measurements were taken using ReDS™ with the goal of keeping lung fluid content within the normal range of 20-35%. Data aggregated in the cloud was sent to physicians to monitor and adjust medication with the goal to keep each patient's fluid status balanced and avoid hospital readmission.\nAs previously announced on January 28, 2019, Medicure entered into an agreement with Sensible Medical Innovations Inc. (\"Sensible\") to become the exclusive marketing partner for ReDSTM in the United States and Medicure continues to hold a 7.71% equity stake on a fully diluted basis in Sensible.\n\"ReDS™ is an easy-to-use, non-invasive, point-of-care tool that we believe should be in the hands of every healthcare team who monitors and manages patients living with heart failure. We are extremely excited about these new results and believe this adds further evidence and value to support the use of ReDS™ as a primary tool...